Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

@article{Gunderson2015OlaparibAO,
  title={Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.},
  author={Camille Gunderson and Kathleen N. Moore},
  journal={Future oncology},
  year={2015},
  volume={11 5},
  pages={
          747-57
        }
}
Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I and II trials and has single-agent activity in both germline BRCA mutated and sporadic ovarian cancer. Phase III trials assessing the efficacy of olaparib in the maintenance setting following first line and platinum-sensitive recurrence are underway for patients with a germline BRCA mutation, given the inherent molecular… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Research Progress on PARP14 as a Drug Target

  • Front. Pharmacol.
  • 2019
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015

The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.

  • International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • 2014

Efficacy of chemotherapy in BRCA 1 / 2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance : a multi - institutional study

P Fenaux, P Morel, JL Lai
  • Clin . Cancer Res .
  • 2013